bioMerieux, Inc. — FDA PCCPs
bioMerieux, Inc. holds 3 FDA-authorized PCCPs in this tracker. Here is the full list, newest first.
- K260160VITEK REVEAL GN AST Assay and VITEK REVEAL AST SystembioMerieux, Inc.2026-07-08Non-AIPanel expansion
- K260282VITEK 2 AST-Streptococcus Inducible Clindamycin ResistancebioMerieux, Inc.2026-04-15Non-AIUnknown
- K251579VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL)bioMerieux, Inc.2025-08-21Non-AIUnknown
Other companies
Want the monitoring teardown?
We read the bioMerieux, Inc. PCCPs in this list, then map the post-market monitoring that its modification protocol requires, including the deployment-period evidence most teams can't reconstruct at modification time. Sentir is the independent system of record that produces it.
Book a callSource: U.S. FDA public records (openFDA 510(k)/De Novo databases and accessdata.fda.gov). PCCP type and category are editorial classifications based on public documents, not official FDA designations.
This page is a factual summary of public FDA records. Sentir Health is not affiliated with or endorsed by the named companies or the U.S. Food and Drug Administration. Spot an error? Request a correction.